Saint Herblain

• Predictive Signature of Benralizumab Response. BENRAPRED Study. Recruiting
  2024-514843-27-00 6 2021-10-11 Severe asthma
• Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting
  2024-513427-17-00 6 2021-05-20 Well controlled severe allergic asthma
• Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast C … Recruiting
  2023-505923-30-00 4 2021-05-11 Patients with hormone-receptor positive (HR+) and human epidermal grow
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• Evaluation of efficacy and tolerance of fludrocortisone (Flucortac) in the treatment of neurogenic orthostatic hypotension Recruiting
  2024-517841-16-00 6 2020-07-09 Neurogenic Orthostatic Hypotension
• Non inferiority study of preoperative chemotherapy without pelvic irradiation for rectal cancer Recruiting
  2024-510580-28-00 5 2019-06-05 Middle or low locally advanced resectable rectal carcinoma
• Avoid Anticoagulation After IntraCerebral Haemorrhage Recruiting
  2024-514094-22-00 5 2019-01-18 Intrecerebral Haemorrhage
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co … Recruiting
  2024-518578-15-00 5 2018-02-05 Is to demonstrate a non inferior efficacy of azithromycin and so the p
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038) Ended recruitment
  2025-521970-33-00 5 2025-12-19 ​​Pulmonary Arterial Hypertension (PAH)
• Weight loss in people living with overweight or obesity following treatment with cagrilintide Ended recruitment
  2024-519530-24-00 5 2025-10-31 Overweight and obesity
• Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) Ended recruitment
  2025-521681-10-00 4 2025-10-02 Lung Cancer
• Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL … Ended recruitment
  2024-520050-38-00 5 2025-09-18 Extensive stage small cell lung cancer (ES-SCLC). S
• A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr … Ended recruitment
  2024-511754-41-00 4 2025-05-29 idiopathic pulmonary fibrosis
• A clinical study of sotatercept in people with pulmonary hypertension (MK-7962-023) Ended recruitment
  2024-515773-99-00 4 2025-05-26 Pulmonary Hypertension
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL C … Ended recruitment
  2024-514032-25-00 4 2024-12-11 Patients with a histilogically confirmed diagnosis of cervical squamou
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph … Ended recruitment
  2023-505989-29-00 5 2024-11-21 Extensive stage small cell lung cancer (ES-SCLC)
• DAPAgliflozine to attenuate cardiac RemOdeling afTEr aCuTe myOcardial infarction Ended recruitment
  2024-511882-13-01 5 2024-11-19 Cardiac failure
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants with … Ended recruitment
  2023-508697-28-00 7 2024-11-13 Frontotemporal Dementia (FTD)
• PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first … Ended recruitment
  2024-518553-41-00 5 2024-11-08 colon cancer and rectal with liver metastasis
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1) Ended recruitment
  2023-509633-39-00 7 2024-08-06 Advanced solid tumours

Showing 145–168 of 301 trials